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Antioxidants have been the focus of studies for developing neuroprotective agents to be used in the therapy for stroke, which is an
acute andprogressive neurodegenerative disorder. Medicagosativa (MS)hasalongtraditionofuseasayurvedicandhomoeopathic
medicineincentral nervoussystemdisorders.Theplanthasbeen reported tohaveantioxidant,anti-inﬂammatoryandantidiabetic
eﬀects. Therefore, the present study was designed to investigate the neuroprotective eﬀect of methanol extract of MS on
ischemia and reperfusion-induced cerebral injury in mice. Bilateral carotid artery occlusion (BCAO) for 15min followed by 24-h
reperfusion, resulted insigniﬁcantelevationininfarctsize,xanthineoxidase(XO)activity, superoxide anion(O
•−
2 )pr oductionand
thiobarbituric acid-reactive substance (TBARS) levels, and signiﬁcant depletion in endogenous antioxidant [reduced glutathione
(GSH), superoxide dismutase (SOD) and total tissue sulfhydryl (T-SH) groups] systems in mice brain. Further, BCAO led to
impairmentin short-term memory and motor coordination.Pre-treatment with MS (100 or 200mgkg−1, p.o.) markedly reduced
cerebral infarct size, XO, O
•−
2 and TBARS levels, signiﬁcantly restored GSH, SOD and T-SH levels and attenuated impairment in
short-termmemoryandmotorcoordination.Inaddition,MSdirectly scavengedfreeradicalsgeneratedagainstastableradical1,1-
diphenyl-2-picrylhydrazyl and O
•−
2 generated in phenazine methosulphate-nicotinamide adenine dinucleotide systems, and also
inhibited XD/XO conversionandresultant O
•−
2 production. The data from this study suggest that treatment with MS enhances the
antioxidant defense against BCAO-induced global cerebral ischemia and exhibits neuroprotective activity.
1.Introduction
Reactive oxygen species (ROS) are involved in cerebral
ischemia, particularly in ischemia and reperfusion (I/R) [1,
2]. Brain is the most susceptible organ to the damage due to
oxidative stress because neurons are rich in polyunsaturated
fatty acids, and levels of endogenous antioxidant enzymes
[superoxide dismutase (SOD), catalase, glutathione peroxi-
dases] and none enzymes (vitamins C and E) in neuronal
tissue are low [3, 4]. Therefore, oxidative stress may con-
tribute to neuronal cell death due to I/R. During I/R insult, a
number of events that predispose the brain to the formation
of ROS may occur. After reperfusion, these events can set oﬀ
a cascade of other biochemical and molecular sequelae such
as the xanthine dehydrogenase/xanthine oxidase (XD/XO)
conversion, leading to production of ROS [5]. Free radicals
are important pathophysiological mediators of cell injury
in stroke [6]. Oxygen radicals, such as superoxide anion
(O•−
2 ), peroxynitrite (ONOO−), hydrogen peroxide (H2O2)
and hydroxyl radical (OH•) are normally produced in very
low amounts by activated microglia and endothelial cells
as products of mitochondrial metabolism [7]. Among the
ROS, O•−
2 was believed to be directly toxic to neurons since
it initiates a free radical-mediated chain reaction causing
additional central nervous system (CNS) damage [8]. In
addition, total sulfhydryl (T-SH) oxidation, mediated by free
radicals released during ischemia, may also contribute to
XD/XO reversible oxidative conversion. Both mechanisms
were suggested to cause a conformational change in ﬂavine
adenine dinucleotide domain of the XD leading to the
formation of XO [9].
Since reperfusion injury is associated with an imbalance
of oxidative stress and antioxidant defense system, theoreti-
cally it would be possible to limit oxidative damage and ame-
liorate disease progression by supplementing antioxidants
[10]. Indeed, several natural and synthetic antioxidants have2 Evidence-Based Complementary and Alternative Medicine
shown neuroprotective eﬀect in I/R-induced cerebral injury
[11, 12]. Although standardized extract of Ginkgo biloba
(EGb761) [13], edaravone [14]o rc u r c u m i n[ 15] have been
demonstrated to be antagonistic to brain I/R, the anti-I/R
agents available are still far from suﬃcient. In recent years,
considerable interest has been generated on a leguminous
plant Medicago sativa (MS) (Leguminosae), which is one
of the most reputed medicinal plant traditionally used to
improve the memory, to cure kidney pain, cough, sore
muscles [16], as rejuvenator, antidiabetic, antioxidant, anti-
inﬂammatory, antimicrobial and in CNS disorders [17, 18].
Moreover, MS has a long tradition of use as ayurvedic and
homoeopathic medicine in CNS disorders [19]. Phytochem-
ical reports onMS indicate that theplant contains ﬂavonoids
[20], alkaloids[21, 22], phytoestrogens, coumarins, digestive
enzymes, triterpenes [23], saponins [24] and phytosterols
[23, 25]. Several clinical and animal studies indicate that
the ingestion of MS reduces cholesterol absorption and
atherosclerotic plaque formation in the arteries [26, 27]. MS
isbeneﬁcialin cardiovascular complaints[23], convalescence
and debility[22], diabetes [28] and also when used as a tonic
after blood loss and during anemia [22]. The plant has been
shown to have anti-tumor activity against certain types of
leukemia cells in mice and selective toxicity in dog cancer
cells grown in vitro [29].
As reported, MS possesses antioxidant, anti-inﬂamma-
tory and antidiabetic activity. However, no work has ever
been carried out to evaluate the neuroprotective eﬀect of MS
on cerebral stroke. Thus, it was considered worthwhile to
investigate the eﬀect of MS on global cerebral I/R-induced
cerebral injury in mice. In addition, direct free scavenging
activity of MS was also evaluated against free radicals
generated against a stable radical 1,1-diphenyl-2-picryl-
hydrazyl (DPPH), and O
•−
2 radical generated in phenazine
methosulphate (PMS)-nicotinamide adenine dinucleotide
(NADH) systems comparable to butylated hydroxytoluene
(BHT) and butylated hydroxyanisole (BHA), to assess its
antioxidant eﬀect.
2.Methods
2.1. Animals. Swiss albino mice of either sex (20–30 g) were
employed in the present study. The animals were maintained
onstandard environmental conditionsand fedwith standard
rodent diet (Kissan Feeds Ltd, Mumbai, India) and tap water
ad libitum. The experimental protocol was approved by the
Institutional Animal Ethics Committee and care of the ani-
mals was carried out as per the guidelines of the Committee
for the Purpose of Control and Supervision of Experiments
onAnimals (CPCSEA),Ministry of Environment and Forest,
Government of India.
2.2. Reagents and Chemicals. Chloral hydrate was obtained
from Reidel-deHaen, Germany. Thiobarbituric acid (TBA),
triphenyltetrazolium chloride (TTC), 1,1,3,3-tetraethoxy-
propane, dithiothreitol (DTT), phenylmethylsulfonyl ﬂuo-
ride (PMSF), xanthine, XO, nitroblue tetrazolium (NBT),
PMS, 5,5 -dithiobis-(2-nitrobenzoic acid) (DTNB), DPPH,
reduced form of NADH, ascorbic acid, BHA and BHT were
purchased from Sigma (Sigma-Aldrich GmbH, Sternheim,
Germany).
2.3. Preparation of MS. Aerial parts of the plant MS were
procured from Himalaya Herbs Stores, Saharanpur, India.
Identity of the plant material was authenticated by the
National Institute of Science Communication and Infor-
mation Resources (NISCAIR), New Delhi vide their letter
no. NISCAIR/RHMD/Consult/2008-09/1170/202 dated 25
February 2009.
Dried aerial parts of the plant were pulverized using a
mechanical grinder. Powderedmaterial (100g)was extracted
with methanol (24h) using the Soxhlet apparatus. There-
after, the resulting methanol extract was reduced in vacuo
(40◦C; N2 stream), freeze-dried and stored at 4◦Cu n t i l
further use in the experiment. The yield was 11.2% (w/w).
Phytochemical screening [30, 31] of the extract revealed the
presence of ﬂavonoids, alkaloids, phytosterols, coumarins,
polyphenols and amino acids.
2.4. Experimental Protocols. A total of ﬁve groups of 16
mice each were employed in the present study. To obtain
maximum data from a small number of animals, half
the animals from each group were subjected to estimate
infarct size, XO, O
•−
2 , thiobarbituric acid-reactive substance
(TBARS),reducedglutathione(GSH),SOD and T-SH levels.
The remaining half of the animals from each group was
subjected to elevated plus-maze test and inclined beam
walking test before global cerebral ischemia and after 24-
h reperfusion. Vehicle or drugs were fed once daily for 10
consecutive days prior to the experiment and treated as
follows.
(i) Group I: Sham group (n = 8 ) .M i c ew e r es u b j e c t e dt o
surgical procedure, a thread was passed below both
carotid arteries but the arteries were not occluded.
After 15min, the thread was removed and the animal
was sutured back and allowed to recover for 24h.
(ii) Group II: Control (vehicle-pre-treated) group (n =
8). Mice were orally administered vehicle (simple
syrup I.P. +Tween80 (5%), 10mLkg−1)1hp r i o rt o
being subjected to 15min of global cerebral ischemia
bybilateralcarotidartery occlusion(BCAO)followed
by reperfusion for 24 h.
(iii) Group III: EGb761-treated group as positive control
(n = 8). Mice were orally administered EGb761 at
ad o s eo f8 0m gk g −1,1hb e f o r es u b j e c t i n gt h e mt o
global cerebral ischemia.
(iv) Group IV: Drug extract-treated group (n = 8). Mice
were orally administered methanol extract of MS
(MS) at a dose of 100mg kg−1,1hb e f o r es u b j e c t i n g
them to global cerebral ischemia.
(v) Group V: Drug extract-treated group (n = 8).
Mice were orally administered MS at a dose of
200mgkg−1, 1h before subjecting them to global
cerebral ischemia.Evidence-Based Complementary and Alternative Medicine 3
Pilot experiments using infarct size as the end point were
performed to choose the doses.
2.5. Bilateral Carotid Arteries Occlusion. Animals were
subjected to BCAO under chloral hydrate anesthesia
(400mgkg−1 i.p.). A cotton thread was passed below each
carotid artery. Pulling the ends of the thread with constant
weight induced global cerebral ischemia. After 15min of
global cerebral ischemia, the weight on the thread was
removed to allow reﬂow of blood through carotid arteries
andtheincisionwassuturedbackinlayers[32].Temperature
was maintained at 37◦C throughout the surgical procedure.
2.6. Cerebral Infarct Size Assessment. After 24h of reper-
fusion, animals were sacriﬁced by spinal dislocation and
the brain was removed. The brain was kept overnight at
−4◦C. Frozen brain was sliced into uniform sections of ∼
1-mm thickness. The slices were incubated in 1% TTC at
37◦Ci n0 . 2Mt r i sb u ﬀer (pH 7.4) for 20min [33]. TTC
is converted to red formazone pigment by nicotinamide
adenine dinucleotide (NAD) and dehydrogenase present in
living cells. Hence viable cells were stained deep red. The
infarcted cells loose these enzymes and, thus, remained
unstained dull yellow. After the end of staining, color images
of these slices were captured using a digital camera (Kodak
7230) and the software Adobe Photoshop 7.0. The size of
infarct was calculated with the computerized image analyzer
(MCID Elite). Percentage infarct volume was calculated
using the following equation:
%Infract volume =
 Infract volume
Total volume ofslice

× 100

.
(1)
2.7. Biochemical Analysis
2.7.1. Estimation of TBARS. The brain was weighted,
minced and suspended in a buﬀer containing 30mM Tris-
hydrochloric acid (HCl) and 2.5mM calcium chloride
(CaCl2 (pH 7.6)). The above mixture was homogenized,
and the homogenate was centrifuged at 750g to separate
cellular debris. The supernatant was accurately divided into
two parts. Both portions were centrifuged at 8200g to obtain
mitochondrial fraction. One was utilized for determination
of TBARS [34] and the other one was employed for protein
estimation [35].
2.7.2. XO Activity and Superoxide Radical Generation
in Xanthine-XO System. The brain was homogenized in
ice-cold saline or phosphate buﬀer (50mM, pH 7.8).
The homogenate in phosphate buﬀer containing ethylene
diaminetetraacetic acid (EDTA) 1mM, DTT 10mM and
PMSF 1mM, was centrifuged at 25000g for 30min at 4◦C
[36]. The supernatant was used for determination of XO
activity and O
•−
2 production. The 25000g supernatant from
the XO homogenizing buﬀer was used for determinations of
the enzymatic activities of XO, total (XO + XD) and %XO of
the total [37]. Another aliquot of the supernatant was used
for the O
•−
2 production [38], expressed as pmol min−1 mg−1
of protein, based on an extinction coeﬃcient Δε550 = 21 ×
103M−1 cm−1 [39].
2.7.3. Superoxide Dismutase. SOD activity was measured by
the method of Kakkar et al. [40]. The mice brains were
homogenized in ice-cold sodium pyrophosphate buﬀer (pH
8.3) in a ratio of 50mgmL−1, and 200μL of this homogenate
was used for the assay. The inhibition by SOD of reduction
of NBT to blue-colored chromogen in the presence of PMS
and NADH was measured at 560nm. One unit of enzyme
activity was deﬁned as enzyme concentration required to
inhibit the absorbance at 560nm of chromogen production
by 50% in 1min under assay conditions, and expressed as
speciﬁc activity in unit of SOD min−1 mg−1 of protein.
2.7.4. Reduced Glutathione. G S Hi nt h eb r a i nw a sd e t e r -
mined by the method of Jollow et al. [41]. A total of 1mL of
PMS (10% w/v) was precipitated with 1mL of sulfosalicylic
acid (4%). The samples were kept at 4◦C for at least 1h
and, then, subjected to centrifugation at 1200g for 15min
at 4◦C. The assay mixture contained 0.1mL of PMS (10%,
w/v), 2.7mL of phosphate buﬀer (0.1M, pH 7.4) and 0.2mL
DTNB (40mg/10mL phosphate buﬀer, 0.1 M, pH 7.4) in
a total volume of 3mL. The yellow color that developed
was read immediately at 412 nm. The enzyme activity was
calculated as nM DTNB oxidized/min per milligram of
protein.
2.7.5. T-SH Groups Assay. This assay was carried out fol-
lowing the method of Sedlack and Lindsay [42]. Brieﬂy, a
200-mg sample of brain tissue was homogenized in 8mL
of 0.02 M EDTA, and 500μL of this was used for the assay.
Measurement of T-SH was done by analyzing the reaction of
SH groups in tissue with DTNB and levels are expressed as
mmol SHmg−1 of proteins.
2.8. Behavioral Testing
2.8.1. Short-Term Memory Evaluation Using Elevated Plus
Maze. Plus maze consists of two enclosed (16 × 5 × 12cm)
and two open (16 × 5cm) arms, connected by a central
platform (5 × 5cm)[43]. It was elevated to a height of25cm
abovetheﬂoor.Alltheanimalsweregivenasingletrialonthe
plus maze. Each mouse was placed individually at the end of
the open arm facing away from central platform of the maze.
Thetimetakenbythemousetoenterfromtheopenarmwith
all the four legs into the enclosed arm was taken as transfer
latency time (TLT) [44, 45].
2.8.2. Inclined Beam Walking Test. To evaluate fore and hind
limb motor coordination, inclined beam walking test was
employed [46]. Inclined beam walking test was performed
before ischemia and 24h after reperfusion.
2.9. Antioxidant Activity of MS In Vitro
2.9.1. Superoxide Anion-Scavenging Activity. Superoxide
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based on the method described by Liu et al. [47]w i t hs l i g h t
modiﬁcation [48]. The superoxide radical is generated in
PMS-NADH systems by oxidation of NADH and assayed by
the reduction of NBT. In this experiment, the superoxide
radicalwasgeneratedin3mLofTris-HClbuﬀer(16mM,pH
8.0) containing 1mL of NBT (50μM), 1mL NADH (78μM)
and sample solution of extract (from 25 to 75μgmL −1)
in water were mixed. The reaction was started by adding
1mL of 10 M PMS to the mixture. The reaction mixture
was incubated at 25◦C for 5min, and the absorbance was
recorded at 560 nm against blank samples. l-Ascorbic acid
was used as a control. The percentage inhibition of O
•−
2
generation was calculated using the following formula:
Inhibition(%) =
(A0 −A1)
A0

× 100, (2)
where A0 wastheabsorbanceofthecontrol(l-ascorbic acid),
and A1 was the absorbance of drug extract and standards.
2.9.2. Free Radical-Scavenging Activity. T h ef r e er a d i c a l -
scavenging activity of MS was measured by DPPH radical
using the method of Shimada et al. [49]. Brieﬂy, 0.1mM
solution of DPPH in ethanol was prepared and 1mL of this
solution was added to 3mL of sample solution of extract
in water at diﬀerent concentrations (25–75μgmL −1). The
absorbance was measured at 517nm. The percent DPPH
radical-scavenging eﬀect was calculated using the following
formula:
DPPH radical scavenging eﬀect (%)
= 100 −
(A0 − A1)
A0

× 100

,
(3)
where A0 was the absorbance of the control reaction and A1
was the absorbance in the presence of the standard sample or
extract.
2.10. Statistical Analysis. All the data are presented as
mean ± SEM. The data of infarct size and biochemical
parameters were statistically analyzed using one-way anal-
ysis of variance (ANOVA) followed by post hoc Tukey’s
multiple range test. The data of percentage change in TLT
was statistically analyzed using repeated-measure ANOVA
followed by post hoc Tukey’s multiple range test. Inclined
beam walking test was statistically analyzed using one-way
ANOVA followed by post hoc Kruskal-Wallis test. A P-value
of <.05 was considered statistically signiﬁcant.
3.Results
3.1. Neuroprotective Eﬀects of MS. Global cerebral ischemia
of 15min followed by reperfusion for 24h produced sig-
niﬁcant increase in cerebral infarct size. Administration of
MS (100 or 200mgkg−1)1 hb e f o r ei s c h e m i am a r k e d l y
attenuated I/R-induced increase in cerebral infarct volume
by 37.9 and 54.8%, respectively (P < .01; Figure 1). Admin-
istration of EGb761 (80mgkg−1) similarly reduced the
infarct volume by 49.6% (P < .01; Figure 1). This suggested
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Figure 1: Eﬀect of methanol extract of MS on brain infarction in
mice subject to global cerebral ischemia followed by reperfusion.
Each column represents the mean ± SEM, n = 8. aP < .05 versus
Sham; bP < .01 versus control (vehicle pre-treated); cP < .05 versus
100mgkg−1,p . o .o ft h ee x t r a c t .
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Figure 2: Eﬀect of methanol extract of MS on % XO activity in
mice subject to global cerebral ischemia followed by reperfusion.
Values expressed as mean ± SEM, n = 8. aP < .05 versus Sham; bP <
.05 versuscontrol (vehiclepre-treated); cP <.05versus100mgkg−1,
p.o. of the extract. % XO = [XO/(XO + XD)] × 100.
that the administration of MS exhibited protective eﬀect
against I/R induced cerebral injury, when compared to
control.
3.2. Antioxidant Eﬀects of MS In Vivo. Figure 2 depicts
that I/R insult (control group) resulted in >2-fold increaseEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of methanol extract of MS on superoxide
anion (O
•−
2 ) production in mice subject to global cerebral
ischemia followed by reperfusion. Values expressed as mean ±
SEM, n = 8. aP < .05 versus Sham; bP < .05 versus control
(vehicle pre-treated); cP < .05 versus 100mgkg−1,p . o .o ft h e
extract.
i n%X Oo ft o t a l( X O+X D )a c t i v i t yi nm o u s eb r a i n
compared with the sham group. This increase was eﬀectively
diminished by 48.2% of control group after administration
of MS (200mgkg−1). The production of O
•−
2 Paralleled the
increasein %XOactivityinmouse ischemicbrainwhere ∼3-
fold increase in O•−
2 production was noted compared to the
sham level (Figure 3). MS signiﬁcantly hampered this free
radicalbursttoabout54%oftheelevatedlevelsofthecontrol
group. Figure 4 shows that TBARS concentration in brain
mitochondria and supernatant fractions was signiﬁcantly
elevated in mouse ischemic brain due to I/R insult. Pre-
treatment with MS signiﬁcantly decreased the elevated
TBARS concentration in brain mitochondria and super-
natant fractions as compared to control group. Likewise,
EGb761 (80mgkg−1) signiﬁcantly suppressed I/R-induced
increase in XO, O•−
2 production and TBARS concentration
to a similar extent.
All biochemical parameters (GSH, SOD and T-SH)
showed a signiﬁcant decrease in the control group versus
the respective sham group. Pre-treatment with MS markedly
reversed the alterations in biochemical parameters brought
aboutby I/R.The valueswere almost restored to near normal
levels with no signiﬁcant diﬀerences versus the sham group.
GSH, SODand T-SH were signiﬁcantly elevated (rather than
showing depletion) in the MS-treated animals subjected to
BCAO and reperfusion injury as compared to the control
group (Table 1). Pre-treatment with EGb761 (80mgkg−1)
signiﬁcantly suppressed oxidative stress to a similar extent.
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Figure 5: Comparison of superoxide anion radical-scavenging
activity of MS, BHA and BHT by the PMS-NADH-NBT method at
the concentration (50μgmL −1). BHA = butylated hydroxyanisole;
BHT =butylated hydroxytoluene. Valuesexpressed asmean ±SEM.
3.3. Antioxidant Activity of MS In Vivo. Direct antioxidant
a c t i v i t yb yM Si ss h o w ni nF i g u r e s5 and 6.A tc o n -
centrations of 25–75μgmL −1, MS exhibited concentration-
dependent scavenging activities against O•−
2 generated in
PMS-NADH systems. MS showed signiﬁcant superoxide
radical-scavenging activity, exhibited higher superoxide
radical-scavenging activity than BHA, but lower than BHT
(P < .05) at the same concentration of 50μgmL −1,w h e r e
BHA and BHT were used as standard radical scavengers.6 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of MS methanol extract on biochemical parameters during cerebral post-ischemic reperfusion (15-min BCAO and 24-h
reperfusion).
Group SOD (Umg−1 protein) T-SH (×10−5 Mmg −1 protein) GSH (nMmg−1 protein)
Sham 102.01 ± 17.91 3.59 ± 0.27 5.51 ± 0.34
Control 65.90 ± 14.39∗∗ 2.34 ± 0.26∗ 2.20 ± 0.92∗∗
EGb761 (80mgkg−1) 97.21 ± 10.52∗∗ 3.42 ± 0.20∗∗∗ 5.54 ± 0.51∗∗
MS (100mgkg−1) 84.45 ± 9.61∗∗ 3.29 ± 0.35∗∗ 3.75 ± 0.61∗∗∗
MS (200mgkg−1) 97.81 ± 12.71∗ 3.47 ± 0.25∗∗∗ 5.57 ± 0.46∗∗
All data are expressed as mean ± SEM, n = 8. Sham and treatment groups are compared with control (vehicle pre-treated). ∗P< .001, ∗∗P< .01, ∗∗∗P< .05.
Statisticalanalysiswas done by one-way ANOVA followed by Tukey’s Test.
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Figure 6: Free radical-scavenging activity of diﬀerent concentra-
tions of MS, BHA and BHT by DPPH radicals. BHA = butylated
hydroxyanisole; BHT = butylated hydroxytoluene. Values expressed
as mean ± SEM.
In another assay, the free radical-scavenging activity of MS
was measured in terms of hydrogen-donating or radical-
scavenging ability against a stable radical DPPH. The scav-
enging eﬀect of MS and standards on the DPPH radical
decreased in the order of BHA > MS > BHT and were 77,
70 and 67% at the concentration of 75μgmL −1, respectively.
These results indicated that MS have a signiﬁcant eﬀect on
scavenging free radicals.
3.4. Behavioral Observations. The training trials performed
on day 2 and day 3 signiﬁcantly decreased the TLT as
compared with TLT on day 1 using elevated plus maze.
Pre-treatment with MS signiﬁcantly prevented I/R-induced
increase in the percentage change in TLT (Figure 7). Global
cerebral ischemia also produced a marked impairment of
motor performance. MS treatment before I/R signiﬁcantly
prevented I/R-induced impairment of motor performance
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Figure 7:Eﬀect ofmethanolextract ofMSonimpairmentofshort-
term memory (% change in TLT) in mice subject to global cerebral
ischemiafollowedby reperfusion. Valuesexpressed asmean±SEM,
n = 8. aP < .05 versus Sham; bP < .05 versus control (vehicle pre-
treated); cP < .05 versus 100mgkg−1,p . o .o ft h ee x t r a c t .
(Figure 8). Similarly, EGb761 pre-treatment markedly atten-
uated behavioral deﬁcits.
4.Discussion
In the present study, the antioxidant and neuroprotective
potentialofMSwasstudiedagainst BCAO-inducedoxidative
stress in mice. Experimental models of stroke have been
developed in animals in an attempt to mimic the events
of human cerebral ischemia. It is well documented that
transient global cerebral ischemia results in neurological
abnormality. Therefore, global cerebral ischemia of short
duration followed by reperfusion has been employed in the
present study.
EGb761, a patented extract from the leaves of the Ginkgo
biloba, is a scientiﬁcally proven natural product widely
used to treat cerebral ischemic disorder and neurological
disorder [13, 50] .E G b 7 6 1w a su s e da sar e f e r e n c et o
examine the neuroprotectiveabilities ofMS in mice from I/REvidence-Based Complementary and Alternative Medicine 7
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Figure8:Eﬀectofmethanolextract ofMSonimpairmentofmotor
performance (score of motor incoordination) in mice subject to
global cerebral ischemia followed by reperfusion. Values expressed
asmean ±SEM,n = 8. aP <.05versus Sham; bP < .05versus control
(vehicle pre-treated).
injury. The present investigations revealed that MS exhibited
neuroprotective activity similar to that shown by EGb761.
Pre-treatment with MS markedly reduced the infarct size
induced by BCAO and produced signiﬁcant protection
against neuronal damage (Figure 1), in harmony with other
studies [51, 52].
TBARS, GSH, SODand T-SH were estimated as an index
to assess the severity of oxidative damage in the brain tissue,
and also the eﬀect of MS on the reversal of the damage
produced by BCAO. All these parameters were markedly
reversedandrestoredtonearnormallevelsinthegroupspre-
treated with MS.
Free radicals are well investigated in the development
of I/R-induced cerebral injury [53, 54]. ROS produces mal-
ondialdehyde (MDA), an end product of lipid peroxidation
(LPO). MDA reacts with TBA and is, thus, estimated as
TBARS [55]. Therefore, MDA was estimated using TBARS
assay to estimate extent of ROS.During ischemia, XD under-
goes irreversible proteolytic conversion to XO, producing
O
•−
2 and H2O2 in the presence of oxygen [53]. O
•−
2 does
not directly induce LPO but can react with NO• to form
cytotoxic ONOO− [56]. In addition, it is well documented
that XO is an important prerequisite factor in the process
of O
•−
2 generation in acute post-ischemic reperfusion injury
[5, 57]. Such ﬁnding is in harmony with our results where
a signiﬁcant rise in % XO was found in mouse brain
after I/R insult. The production of O•−
2 paralleled the
rise in % XO activity where a signiﬁcant increase in O
•−
2
generation resulted in untreated control group compared
to the sham group. In the current study, the elevated %
XO activity of the untreated control group was eﬀectively
counteracted by administration of MS. Moreover, it also
signiﬁcantly hampered O
•−
2 burst to about half the value
of the untreated control group. One proposed mechanism
underlying this protective eﬀect of MS, in the model used in
the present investigations, could be through its antioxidant
properties, restoring endogenous antioxidant levels and,
therefore, detoxifying free radicals.
The overproduction of free radicals can be detoxiﬁed
by endogenous antioxidants causing their cellular stores
to be depleted [58]. Glutathione is considered a central
component in the antioxidant defenses of cells. It acts both
to directly detoxify ROS and as a substrate for various perox-
idases [59]. Moreover, it is well evidenced that SOD activity
in serum is reduced in stroke patients, and replacement of
antioxidantactivitycouldbebeneﬁcialintheacutetreatment
of cerebral ischemia [60]. Similarly, fall in T-SH reﬂects the
consumption of tissue thiols. As such, fall in GSH during
cerebral reperfusion injury is well reported [61]. Sulfhydryl
compounds are considered important endogenous antioxi-
dants. They have role in maintenance of cellular proteins and
lipids in their functional states [62]. Pre-treatment with MS
signiﬁcantly elevated GSH, SOD and prevented fall in T-SH
in control groups.
Hippocampal neurons, which are involved in the regu-
lation of short-term memory, are highly susceptible to I/R-
induced injury [63]. Therefore, elevated plus maze has been
employed in present study to evaluate impairment of short-
term memory as a result of cerebral I/R. Cerebral ischemia is
documented to impair sensory motor ability [64]a n dt h u s
inclined beam walking test has been used in the present
study to investigate the eﬀect of cerebral I/R on motor
performance.
In conclusion, the present ﬁndings suggest a potential
role of MS in cerebral stroke, and the ﬁndings are important
in view of the fact that stroke is at present the second
leading cause of death worldwide [65]. The mechanisms by
which MS normalized the cerebral damage and stress, and
prevented impairment of short-term memory and motor
incoordination, is probably the antioxidant property of the
drug which was evaluated in vitro, to direct scavenged
free radical generated against a stable radical DPPH and
O
•−
2 radical generated in PMS-NADH systems, and its
inhibitory eﬀects on XD/XO conversion and resultant O
•−
2
production. Further studies are warranted to pursue the
interesting lead emerging from the present results to exploit
the full therapeutic potential of MS in cerebrovascular
diseases.
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